reports
NRG Energy Inc: 1 director
A director at NRG Energy Inc sold 24,546 shares at 83.410USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase...
Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in The New England Journal of Medicine NOTUS results confirm landmark data from the Phase 3 BOREAS trial and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic obstructive pulmonary disease (COPD) with evidence of type 2 inflammation Data support the potential of Dupixent as the first new treatment approach in more than a decade and first-ever targeted therapy for COPD TARRYTOWN, N.Y. and PARIS...
Regeneron Pharmaceuticals Inc: 2 directors
Two Directors at Regeneron Pharmaceuticals Inc sold after exercising options/sold 122,830 shares at between 974.303USD and 979.225USD. The significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary ...
Ligand Pharmaceuticals Inc: 2 directors
Two Directors at Ligand Pharmaceuticals Inc sold/sold after exercising options 14,227 shares at between 83.205USD and 86.665USD. The significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades...
More than $9 Million Awarded to High School Scientists and Engineers a...
More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024 Grace Sun, 16, receives $75,000 Top Award for a new kind of organic electrochemical transistor at the world’s largest pre-college science, technology, engineering and math (STEM) competition. TARRYTOWN, N.Y. and WASHINGTON, D.C., May 17, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) announced that Grace Sun, 16, of Lexington, Kentucky, won the $75,000 top award, the George D. Yancopoulos Inno...
Sunrun Releases 2023 Impact Report
Sunrun Releases 2023 Impact Report Seventh annual Impact Report highlights Sunrun’s continued progress toward its impact goals, social and environment stewardship, and operating responsibly SAN FRANCISCO, May 16, 2024 (GLOBE NEWSWIRE) -- Sunrun (Nasdaq: RUN), the nation’s leading provider of clean energy as a subscription service, today released its . The report details the company's progress toward its impact goals, social and environmental initiatives, as well as advancements in safety, employee experience, and governance. It also highlights Sunun’s commitment to generating long-term,...
Venus Concept Announces First Quarter of Fiscal Year 2024 Financial Re...
Venus Concept Announces First Quarter of Fiscal Year 2024 Financial Results TORONTO, May 15, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced financial results for the three months ended March 31, 2024. First Quarter 2024 Summary & Recent Progress: Company continues to execute against Transformational Plan Cash used in operations of $2.9 million, down 51% year-over-year from $5.9 millionCash system revenue in first quarter 2024 represented approximately 75% of total syst...
- Michael Pachter
- Nick McKay
Editas Medicine Inc: 1 director
A director at Editas Medicine Inc bought 45,000 shares at 5.642USD and the significance rating of the trade was 82/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...
Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Tri...
Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that two abstracts, including one oral presentation and one poster presentation, detailing clinical data from the RUBY and EdiTHAL trials of renizgamglogene autogedtemcel (reni-cel) have been accepted for presentation at the European Hematology Association (EHA) Hybrid Congress being held June 13-16, 20...
New Post-Hoc Analysis of Pooled Phase 3 Data Shows That INPEFA® (Sotag...
New Post-Hoc Analysis of Pooled Phase 3 Data Shows That INPEFA® (Sotagliflozin) Reduced Risk of Heart Failure Events in Patients With Preserved Ejection Fraction Analysis adds to the body of evidence differentiating INPEFA as a dual oral inhibitor of SGLT2 and SGLT1 THE WOODLANDS, Texas, May 14, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced a new post-hoc analysis of clinical data showing that INPEFA® (sotagliflozin), a dual oral inhibitor of SGLT2 and SGLT1, reduced the risk of heart failure-related events across a diverse population of patients, including patients with pres...
Magnite to Participate in Upcoming Financial Conferences
Magnite to Participate in Upcoming Financial Conferences NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- Magnite (Nasdaq: MGNI), the largest independent sell-side advertising company, today announced that members of its executive team will participate and host in-person investor meetings at the following financial conferences: 19th Annual Needham Technology, Media and Consumer Conference in New York City on Tuesday, May 14 and Wednesday, May 15. Management will present on May 15 at 10:15 a.m. ET.B. Riley Securities 24th Annual Investor Conference in Beverly Hills on Wednesday, May 22 and Thur...
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatm...
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP) If approved, Dupixent would be the first treatment in the U.S. indicated for adolescents aged 12-17 years with inadequately controlled CRSwNP, a condition driven in part by underlying type 2 inflammation that obstructs the sinuses and nasal passages and can lead to a loss of sense of smell Current treatment options for adolescents with CRSwNP leave many patients with uncontrolled disease and often result in the recurrence of nasal polyps TARRY...
Editas Medicine Preclinical Data Highlights Advancement of in vivo Gen...
Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting Research includes the first-ever application of AsCas12a in vivo, optimized LNP delivery, and gene editing RNA guide modifications Data to support development of the Company’s in vivo gene editing medicines pipeline CAMBRIDGE, Mass., May 10, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced the presentation of preclinical data demonstrating several in viv...
- Wedbush Research
GEO GEO GROUP INC. (THE)
2454 MEDIATEK INC.
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
WDC WESTERN DIGITAL CORPORATION
TSLA TESLA INC
TSCO TRACTOR SUPPLY COMPANY
TRIP TRIPADVISOR INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
SBRA SABRA HEALTH CARE REIT INC.
QCOM QUALCOMM INC
PZZA PAPA JOHN'S INTERNATIONAL INC.
PSTG PURE STORAGE INC. CLASS A
OHI OMEGA HEALTHCARE INVESTORS INC.
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
NHI NATIONAL HEALTH INVESTORS INC.
MU MICRON TECHNOLOGY INC.
LTC LTC PROPERTIES INC.
LOW LOWE'S COMPANIES INC.
JCOM J2 GLOBAL INC.
INTC INTEL CORPORATION
HD HOME DEPOT INC.
GOOGL ALPHABET INC. CLASS A
35G GENPACT LIMITED
FB FACEBOOK INC. CLASS A
FATE FATE THERAPEUTICS INC
CXW CORECIVIC INC.
CRM SALESFORCE.COM INC.
CHUY CHUY'S HOLDINGS INC.
AXTI AXT INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
FND FLOOR & DECOR HOLDINGS INC. CLASS A
ANAB ANAPTYSBIO INC.
OKTA OKTA INC. CLASS A
SNBR SLEEP NUMBER CORPORATION
MDB MONGODB INC. CLASS A
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
AVGO BROADCOM INC.
PRPL PURPLE INNOVATION
LEGH LEGACY HOUSING CORP
CRNC CERENCE
SMCI SUPER MICRO COMPUTER
U INC.
PLTR UNITY SOFTWARE
VOR PALANTIR TECHNOLOGIES
PLTK VOR BIOPHARMA
SNOW PLAYTIKA HOLDING
RBLX SNOWFLAKE INC. CLASS A
GHLD ROBLOX
MRVL GUILD HOLDINGS
STX MARVELL TECHNOLOGY INC
ALIT SEAGATE TECHNOLOGY HLDGS PLC
UWMC FOLEY TRASIMENE ACQUISITION CORP
ATXS UWM HLDGS CORP
CCSI ASTRIA THERAPEUTICS INC
GFS CONSENSUS CLOUD SOLUTIONS INC
TYRA GLOBALFOUNDRIES INC
SOUN TYRA BIOSCIENCES INC
GETY SOUNDHOUND AI INC
GTBIF GETTY IMAGES HOLDINGS INC
SKLZ GREEN THUMB INDUSTRIES INC.
DNTH SKILLZ INC
DIANTHUS THERAPEUTICS INC
- Michael Pachter
- Nick McKay
Lexicon Pharmaceuticals to Participate in the Bank of America Securiti...
Lexicon Pharmaceuticals to Participate in the Bank of America Securities Healthcare Conference 2024 THE WOODLANDS, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced its participation in the Bank of America Securities Healthcare Conference 2024. Jeff Wade, Lexicon’s president and chief financial officer, will make a company presentation on Tuesday, May 14, 2024, at 8:00 am PDT (11:00 am ET). A simultaneous webcast will be available in the “Events” section of the Lexicon website at , and a recording of the webcast will be available for two weeks following the original...
Applied Therapeutics Reports First Quarter 2024 Financial Results
Applied Therapeutics Reports First Quarter 2024 Financial Results Govorestat NDA for Classic Galactosemia under Priority Review, PDUFA target action date of November 28, 2024 Govorestat MAA under review by EMA; Day 120 3-month clock-stop extension granted; decision expected in early Q1 2025Company discussing potential NDA submission under Accelerated Approval for govorestat for treatment of SORD Deficiency with Neurology I Division of FDA NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT) (the “Company”), a clinical-stage biopharmaceutical company devel...
Vaxcyte Reports First Quarter 2024 Financial Results and Provides Busi...
Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update -- VAX-31 Adult Phase 1/2 Study Enrollment Completed; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024 -- -- Following VAX-31 Adult Phase 1/2 Study Readout, Vaxcyte to Advance VAX-24 or VAX-31 to Adult Phase 3 Program -- -- VAX-24 Infant Phase 2 Study Enrollment Completed; Topline Data from Primary Immunization Series Expected by End of First Quarter of 2025, Followed by Topline Data from Booster Dose by End of 2025 -- -- $1.9 Billion in Cash, Cash Equivalents and Inves...
Magnite Reports First Quarter 2024 Results
Magnite Reports First Quarter 2024 Results Total Revenue Grows 15% & Contribution ex-TAC(1) Grows 12% Year-Over-Year Contribution ex-TAC(1) from CTV Grows 18% Year-Over-Year NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- Magnite (NASDAQ: MGNI), the world's largest independent sell-side advertising company, today reported its results of operations for the quarter ended March 31, 2024. Q1 2024 Highlights: Revenue of $149.3 million, up 15% year-over-yearContribution ex-TAC(1) of $130.6 million, up 12% year-over-yearContribution ex-TAC(1) attributable to CTV of $54.9 million, up 18% year-over...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.